

Daftar Pustaka

- Agarwal, R. Nissenson, Ar. Battle, D. Coyne, Dw. Trout, Jr. Warnock, Dg. Prevalence, Treatment, And Control Of Hypertension In Chronic Hemodialysis Patients In The United States. *Am J Med.* 2003;115:291–297.
- Andersen, Mj. Agarwal, R. Etiology And Management Of Hypertension In Chronic Kidney Disease. *Med Clin N Am.* 2005;89:525–547.
- Ahmad, Razi. Anwar, Habib. Sana, Rehman. Management Of Hypertension In Patients With End-Stage Renal Disease Leading To Haemodialysis: A Challenge International Journal Of Advances In Medicine Razi A Et Al. *Int J Adv Med.* 2016 Nov;3(4):790-798.
- Amann, Kerstin. Ivan, Rychl Tk. Gabriel, Miltenberger-Milteny. Eberhard, Ritz. Left Ventricular Hypertrophy In Renal Failure Department Pathology And Internal Medicine. University Of Heidelberg, Heidelberg, Germany. *Kidney International*, Vol. 54, Suppl. 68 (1998), Pp. S-78 –S-85
- Aoki, J. Ikari, Y. Nakajima, H. Mori, M. Sugimoto, T. Hatori, M. Tanimoto, S. Amiya, E. Hara, K. Clinical And Pathologic Characteristics Of Dilated Cardiomyopathy In Hemodialysis Patients. *Kidney Int* 2005; 67: 333–340.
- Astor Et Al. In Press That Likely Prevents The Reversibility Of LVH In Uremic Archives Of Internal Medicine. 2002.
- Bargman. Joanne, M. Chapter 11 : Chronic Kidney Disease. *Harrison's Nephrology And Acid-Base Disorders.* 2013. P : 123-140.
- Bayauli, MP. Lepira, FB. Kayembe, PK. Left ventricular hypertrophy and geometry in type 2 diabetes patients with chronic kidney disease. An echocardiographic study. *Cardiovascular Journal Of Africa* Vol 23, No 2, March 2012.
- Bethesda, Md. The National Institutes Of Health, National Institute Of Diabetes And Digestive And Kidney Diseases. 2005. *US Renal Data System:USRDS 2005 Annual Data Report.*
- Chang, Jer-Ming. Szu-Chia, Chen. Jiun-Chi, Huang. Ho-Ming. Hung-Chun, Chen. Anemia And Left Ventricular Hypertrophy With Renal Function Decline And Cardiovascular Events In Chronic Kidney Disease. *The American Journal of the Medical Sciences* Volume 347 Number 3, March 2014.
- Coresh, J. Selvin, E. Stevens, La. Manzi, J. Kusek, Jw. Eggers, P. Van Lente, F. Levey, As. Prevalence Of Chronic Kidney Disease In The United States. *Jama* 2007; 298:2038–2047.
- Cottone, S. Vadala, A. Vella, Mc. Contorno, A. Cerasola, G. Comparison Of Tumor Necrosis Factor And Endothelin-1 Between Essential And Renal Hypertensive Patients. *J Hum Hypertens* 1998; 12: 351–354.
- Chobanian, AV. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 7. 2003
- Das, Evcimen N. King, Gl. The Role Of Protein Kinase C Activation And The Vascular Complications Of Diabetes. *Pharmacol Res* 2007; 55(6): 498–510.

- Di Lullo, L. Floccari, F. Polito, P. Right Ventricular Diastolic Function In Dialysis Patients Could Be Affected By Vascular Access. *Nephron Clin Pract* 2011; 18:C258–C262.
- Dipiro, J. Talbert, Rl. Yee, G. Matze, G. Wells, B. Posey, Lm. *Pharmacotherapy: A Pathophysiologic Approach*, 8th Ed. Chapter 15 : Hypertension. The Mcgraw-Hill Companies; 2011.
- Foley, Rn. Parfey, Ps. Harnett, Jd. Left Ventricular Hypertrophy In Dialysed Patients. *Semin Dial* 5:34–41, 1992.
- Foley, Rn. Parfrey, Ps. Hamett, Jd. Kent, Gm. Munay, Dc. Barre, Pe. The Impact Of Anaemia On Cardiomyopathy, Morbidity And Mortality In End- Stage Renal Disease. *Am J Kidney Dis* 1996;28:53-61.
- Foley, Rn. Herzog, Ca. Collins, Aj. Smoking And Cardiovascular Outcome In Dialysis Patients. *Kidney Int.* 2003;63(4):1462-7.
- Foley, Rn. Curtis, Bm. Randell, Ew. Parfrey, Ps. Left Ventricular Hypertrophy In New Hemodialysis Patients Without Symptomatic Cardiac Disease. *Clin J Am Soc Nephrol* 2010; 5 : 8 05–813.
- Gal-Moscovici, A. Sprague, Sm. Bone Health In Chronic Kidney Disease-Mineral And Bone Disease. *Adv Chronic Kidney Dis* 2007; 14:7-36.
- Glasscock, Rj. Pecoits-Filho, R. Barberato, Sh. 2009. Left Ventricular Mass In Chronic Kidney Disease And Esrd. *Clin J Am Soc Nephrol* 4(Suppl 1), P : S79– S91
- Guidelines Committee. 2003 European Society Of Hypertension–European Society Of Cardiology Guidelines For The Management Of Arterial Hypertension. *J Hypertens* 2003; 21: 1011–1053.
- Horina, Jh. Schwabeger G. Brussee H. Et Al: Increased Red Cell 2,3-Diphosphoglycerate Levels In Haemodialysis Patients Treated With Erythropoietin. *Nephrol Dial Transplant* 8:1219–1222, 1993.
- Inker, LA. Astor, BC. Fox, CH. Isakova, T. Lash, JP. Peralta, CA. Kurella, Tamura M. Feldman, HI. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the evaluation and management of CKD. *American Journal Kidney.* 2014
- Jae-Hwan, Lee. Jae-Hyeong, Park. Role Of Echocariography In Clinical Hypertension. *Clinical Hypertension.* 2013.
- Juan M.et al. Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients. *Kidney International* 1998;54suppl.68:S-92–s-98.
- Laddha, Mukesh. Et Al. 2014. Echocardiographic Assessment Of Cardiac Dysfunction In Patients Of End Stage Renal Disease On Haemodialysis. *Journal Of The Association Of Physicians Of India* Vol. 62 (Jan), P : 28-33.
- Lang, Rm. Bierig, M. Devereux, Rb. Flaszskampf, Fa. Foster, E. Pellikka, Pa. Et Al. Reccomendation For Chamber Quantification: A Report From American Society Of Echocardiography’s Guidelines And Standar Commite And The Chamber Quantification Writing Group, Developed In Conjunction With The

- European Association Of Echocardiography, A Branch Of The European Society Of Cardiology. *J Am Soc Echocardiogr*, 2005; 18: 1440-1463.
- Lang, Rm. Bierig, M. Devereux, Rb. Flaszskampf, Fa. Foster, E. Pellikka, Pa. Et Al. Recommendation For Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society Echocardiography and the European Association of Cardiovascular Imaging. *European Heart Journal – Cardiovascular Imaging* 2015; 16: 233-271.
- Levin, A. Singer, J. Thompson, C.R. Ross, H. Lewis, M. 1996. Prevalent Left Ventricular Hypertrophy In The Predialysis Population: Identifying Opportunities For Intervention. *American Journal Of Kidney Disease* 27 (Mar), P 347-354.
- Levin, Adeera. *Kidney International*, Vol. 61, Supplement 80 (2002), Pp. S35–S38
Anemia And Left Ventricular Hypertrophy In Chronic Kidney Disease Populations: A Review Of The Currentstate Of Knowledge University Of British Columbia, Vancouver, British Columbia, Canada
- Macleod, Alison. *Diagnosis And Management Of Chronic Kidney Disease. Scottish Intercollegiate Guidelines Network*. 2008. P 3-14
- Mailloux, Lu. Levey, As. Hypertension In Chronic Renal Disease. *Am J Kidney Dis* 32:S120-S141, 1998 (Suppl 3).
- Mcclellan, W. Aronoff, Sl. Bolton, Wk. Hood, S. Lorber, Dl. Tang, Kl. Tse, Tf. Wasserman, B. Leiserowitz, M. The Prevalence Of Anemia In Patients With Chronic Kidney Disease. *Curr Med Res Opin* 2004;20:1501—10.
- Mcphee, Sj. Hammer, Gd. *Pathophysiology Of Disease: An Introduction To Clinical Edicine*, 6th Ed. The McGraw-Hill Companies, Inc.; 2006: 301.
- Muntner, P. He, J. Astor, Bc. Et Al. Tarditional And Non Traditional Risk Factor Predict Coronary Heart Disease In Chronic Kidney Disease: Result From The Atherosclerosis Risk In Community Study. *J Am Soc Nephrol* 2005; 16: 3748-54.
- Myers, Danny. *Left Ventricular Hypertrophy*. 2013.
- National High Blood Pressure Education Program Working Group. 1995 Update Of The Working Group Reports On Chronic Renal Failure And Renovascular Hypertension. *Arch Intern Med* 156: 1938–1947, 1995.
- O' Zkaha, M. Ok, E. Cirit, M. Aydm, S. Ak Ci.Cek F. Mees Ejd. Regression Of Left Ventricular Hypertrophy In Hemodialysis Patients By Volume Control Without Antihypertensive Drugs. *Nephrol Dial Transplant*.
- Palacios Cr. Goyal P. Thompson Am. Deschaine B. Systolic Blood Pressure Values Might Further Risk-Stratify The Adverse Outcomes Of Lvh In Older Patients With Chronic Kidney Disease. *Clinical Hypertension* 2016; 22:21.
- Parfrey, Ps. Foley, Rn. Harnett, Jd. Et Al. Outcome And Risk Factors For Left Ventricular Disorders In Chronic Uremia. *Nephrol Dial Transplant* 11:1277–1285, 1996.
- Ratchlife, Pj. *Molecular Biology Of Erythroprotein*. *Kidney Int* 1993;44: 887-904.

- Ritz, E. Metabolic Syndrome And Kidney Disease. *Blood Purif* 2008;26(1): 59–62.
- Rocco, Mv. Flanagan, Mj. Beaver, S. Frederick, P. Gentile, Di. Mcclellan, Wm. Polder, J. Prowant, Bf. Taylor, L. Helgersson, Sd. Report From The 1995 Core Indicators For Peritoneal Dialysis Study Group. *Am J Kidney Dis* 30:165–173, 1997.
- Sarafidis, Pa. Li S. Chen, Sc. Collins, Aj. Brown, Ww. Klag, Mj. Bakris, Gl. Hypertension Awareness, Treatment, And Control In Chronic Kidney Disease. *Am J Med* 2008; 121:332–340.
- Schillaci, G. Verdecchia, P. Porcellati, C. Cuccurullo, O. Cosco, C. Perticone, F. Continuous Relation Between Left Ventricular Mass And Cardiovascular Risk In Essential Hypertension *Hypertension* 2000; 35: 580–586.
- Silberberg, Js. Racine, N. Barre, P. Sniderman, Ad: Regression Of Left Ventricular Hypertrophy In Dialysed Patients Following Correction Of Anemia With Recombinant Human Erythropoietin. *Can J Cardiol* 6:1– 4, 1990].
- Suwitra, Ketut. Penyakit Ginjal Kronik. Buku Ajar Ilmu Penyakit Dalam Edisi Keenam Jilid Ii. 2014. Hal. 2159-2165.
- Takahashi, A. Takase, H. Toriyama. Candisartan, An Angiotensin Ii Type-1 Receptor Blocker, Reduces Cardiovascular Events In Patients On Chronic Haemodialysis -A Randomized Study. *Nephrol Dial Transplant*. 2006;21:2507-12.
- Tomilina NA, Storozhakov GI, Gendlin GE, Badaeva SV, Zhidkova DA, Kim IG, Borisovskaia SV, Loss KE, Fedorova ND. Risk Factor and pathogenetic mechanism of leftventricular hypertrophy in progressive chronic kidney disease and after tranplantation of the kidney. 2007
- Vakili, B. Okin, P. Devereux, Rb. Prognostic Implications Of Left Ventricular Hypertrophy. *Am Heart J* 2001 vol. 141: 334–341.
- Vijan, Sg. Manning, G. Millar-Craig, Mw. How Reliable Is The Electrocardiogram In Detecting Left Ventricular Hyperthrophy In Hypertension? *Postgrad Med J* 1991 67 (789) : 646-648.
- Weinerde.Tighiouarth. Aminmg. Starkpc. Macleodb. Griffith, Jl. Salem, Dn. Levey, As. Sarnak, Mj. Effects Of Anemia And Left Ventricular Hypertrophy On Cardiovascular Disease In Patients With Chronic Kidney Disease. *J Am Soc Nephrol* 16: 1803–1810, 2005.
- Weinerde. Tighiouarth. Aminmg. Starkpc. Macleodb. Griffith, Jl. Salem, Dn. Levey, As. Sarnak, Mj. Chronic Kidney Disease As A Risk Factor For Cardiovascular Disease And All-Cause Mortality: A Pooled Analysis Of Community-Based Studies. *J Am Soc Nephrol* 15: 1307–1315, 2004.
- Wexler, Randy. Aukerman, Glen. Nonpharmacologic strategies for Managing Hypertension. *American Family Physician*. Volume 73, Number 11, June 2006. 1953-1956
- Wing, Aj. 1984. Cardiovascular Related Causes Of Death And Fate Of Patients With Renovascular Disease. *Contributions To Nephrology* Vol.41, P : 306-311.

- Yogiantoro, M. Pendekatan Klinis Hipertensi. Buku Ajar Ilmu Penyakit Dalam Edisi Keenam Jilid Ii. 2014. Hal. 2259-2265.
- Yusuf, S. Hawken, S. Ounpuu, S. Et Al. Effect Of Pottentially Modifiable Risk Factors Associated With Myocardial Infarction In 52 Countries (The Interheart Study): Case Control Study Lancet. 2004 ; 364:937-952.